U.S. Markets open in 4 hrs 36 mins
  • S&P Futures

    3,253.25
    -49.00 (-1.48%)
     
  • Dow Futures

    26,162.00
    -395.00 (-1.49%)
     
  • Nasdaq Futures

    11,122.00
    -220.75 (-1.95%)
     
  • Russell 2000 Futures

    1,540.10
    -18.30 (-1.17%)
     
  • Crude Oil

    36.23
    +0.06 (+0.17%)
     
  • Gold

    1,870.60
    +2.60 (+0.14%)
     
  • Silver

    23.35
    -0.01 (-0.02%)
     
  • EUR/USD

    1.1666
    -0.0012 (-0.1050%)
     
  • 10-Yr Bond

    0.8350
    0.0000 (0.00%)
     
  • Vix

    39.19
    -1.09 (-2.71%)
     
  • GBP/USD

    1.2915
    -0.0008 (-0.0620%)
     
  • USD/JPY

    104.3970
    -0.2130 (-0.2036%)
     
  • BTC-USD

    13,265.93
    -108.25 (-0.81%)
     
  • CMC Crypto 200

    259.84
    +17.16 (+7.07%)
     
  • FTSE 100

    5,579.19
    -2.56 (-0.05%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

Aphria Inc. (APHA) Stock Sinks As Market Gains: What You Should Know

Zacks Equity Research
·2 mins read

Aphria Inc. (APHA) closed the most recent trading day at $4.40, moving -0.68% from the previous trading session. This change lagged the S&P 500's 0.53% gain on the day. At the same time, the Dow added 0.13%, and the tech-heavy Nasdaq gained 1.42%.

Heading into today, shares of the company had lost 6.14% over the past month, lagging the Medical sector's loss of 1.05% and the S&P 500's loss of 3.76% in that time.

APHA will be looking to display strength as it nears its next earnings release. Meanwhile, our latest consensus estimate is calling for revenue of $116.52 million, up 21.97% from the prior-year quarter.

APHA's full-year Zacks Consensus Estimates are calling for earnings of -$0.06 per share and revenue of $521.23 million. These results would represent year-over-year changes of 0% and +28.27%, respectively.

It is also important to note the recent changes to analyst estimates for APHA. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. APHA is currently sporting a Zacks Rank of #4 (Sell).

The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 179, which puts it in the bottom 30% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow APHA in the coming trading sessions, be sure to utilize Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Aphria Inc. (APHA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research